Brexit: the impact on supplementary protection certificates (SPCs)

On 6 February 2019 the House of Commons and House of Lords approved The Patents (Amendment) (EU Exit) Regulations 2018 (Patent SI), which, if it is signed into law, will come into force on Brexit day (i.e. 29 March 2019 or such later date as agreed as part of an extension).

Payments: SEPA - A successful transition

The European Payments Council Board has announced that it has approved the application from UK Finance for the continued participation of UK payment service providers in the SEPA schemes after 29 March 2019 in the event of a no-deal Brexit.

Brexit and your prospectuses

The events surrounding the Brexit negotiations continue to be in a state of flux - but we do have some clarity around the status of the Prospectus Regulation in the UK whatever the outcome of the UK Government's negotiations with the EU.

Poland: official position of the competent authority on consequences for medical devices in the event of a no-deal Brexit

On 1 March 2019, the President of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products issued yet another communique concerning consequences of Brexit, this time with respect to the medical devices.

Life Sciences in Poland: Post-registration changes in case of no-deal Brexit

On 25 February 2019, the President of the Polish Office for the Registration of Medicinal Products, Medical Devices, and Biocidal Products issued a communique concerning the necessary post-registration changes in the event of a “no-deal” Brexit.

Do you need Temporary Permissions in the UK?

In the continued absence of a deal between the UK and the EU and with only 6 weeks to go until Brexit, we have prepared a Guide to the UK regimes which have been designed to enable EU Financial Institutions to continue operations in the UK in the event of a 'no deal' Brexit.

No passport, no loan?

The first signs of spring remind us that EU Exit day is fast approaching but a deal between the EU and the UK is proving elusive. If passporting rights are lost what impact will that have on existing and new corporate loans made by UK lenders into Europe?

Can Brexit frustrate a lease? High Court says No Deal

The High Court has handed down judgment in the closely watched case of Canary Wharf (BP4) T1 Limited and others v European Medicines Agency.  In what will be viewed as a relief for the property industry, the Court has held that the European Medicines Agency remains bound by the terms of its lease, notwithstanding Brexit.

Read our blog and listen to our podcast here.

Transition without a transition period: EIOPA issues recommendations on continuity of insurance contracts following no-deal Brexit

On 19 February 2019, the European insurance regulator EIOPA released recommendations for the insurance sector, calling on national supervisory authorities (“NCAs“) in the EU27 to minimise the detriment to insurance policyholders and beneficiaries in case of a no-deal Brexit

UK sanctions legislations rushes through Parliament in advance of a potential no-deal Brexit

Transposing more than 40 years of EU legislations is not straightforward, including when it comes to EU sanctions laws. In this context, UK secondary legislations are needed to replace references in sanctions laws to Member States and the EU with references to the UK and replace references to the competent authorities with references to the UK Treasury.

A Pragmatic Approach to Rules of Origin in the UK's "rolled-over" FTAs

The United Kingdom ("UK") is gearing up to "roll-over" the EU network of Free Trade Agreements ("FTA") once Brexit takes effect. In the past few weeks, the UK announced that it had successfully rolled-over the FTAs that the EU had concluded with: Switzerland, Chile, the Faroe Islands; and some of the members of the Eastern and Southern Africa Economic Partnership Agreement. The rules of origin included in these UK FTAs set out an interestingly pragmatic strategy that will allow UK manufacturers to both continue relying on EU27 inputs in their production and to maintain preferential access for their goods to those countries.

Brexit: “placing on the EU market” of products inc. medical devices

On 1 February 2019, the European Commission published a new Q&A document to give further guidance on the Notice to stakeholders-withdrawal of the United Kingdom and EU rules in the field of industrial products (“the Notice”). This Notice applies, among others, to medical devices, active implantable medical devices and in vitro medical devices. The Q&A document provides concrete guidance on the concept of products placed on the Union market before Brexit and the transfer of Notified Bodies certificates.